BPM 42522
/ BPGbio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 13, 2021
[VIRTUAL] Utility of S. cerevisiae genetic interactions in the mechanistic validation and therapeutic potential of highly conserved targets for drug discovery
(AACR 2021)
- "Moreover, these alterations were mutually exclusive with 96 reported cancer driver genes. Validation of the candidate genetic interactors for synthetic lethality with BPM42522 and their role in specific cancer types highlights the approach for rapid identification of synthetic lethality and its potential use to stratify patient populations most likely to benefit from therapeutic agents targeting highly conserved drug targets."
Endometrial Cancer • Lung Cancer • Mesothelioma • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Sarcoma • Solid Tumor • Uterine Cancer • BUB1B • CCNB1 • FBXW7 • NEK3 • NF1
April 14, 2021
BERG Announces Oncology Pipeline Advancements And Biomarker Developments For Clinical Decision Support In Breast Cancer At AACR
(PRNewswire)
- "BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced four presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from April 9-14th, 2021....'BERG's platforms, such as BPM 31510 and BPM 42522, are creating valuable assets to help patients during these uncertain times in the areas of breast cancer decision-making, leading protein degradation drug development and skin cancers.'"
Clinical data • Breast Cancer • Oncology
1 to 2
Of
2
Go to page
1